Home › Compare › SLMXF vs ABBV
SLMXF yields 4065.04% · ABBV yields 3.06%● Live data
📍 SLMXF pulled ahead of the other in Year 1
Combined, SLMXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SLMXF + ABBV for your $10,000?
Slam Exploration Ltd., a resource company, engages in the acquisition, exploration, and development of exploration and evaluation properties in Canada. It primarily explores for gold, silver, base metal, and rare earth metals. The company's flagship project is the Menneval gold project that consists of 8 mineral claims comprising 580 claim units covering an area of 12,450 hectares situated in New Brunswick. The company also holds interest in Benjamin REE property; Birch Lake project; Eighteen Mile property; Jake Lee Gold property; McNair property; Mt. Blair Property; Mt. Victor property; and Flume Ridge Gold property, which comprises 76 claim units covering 1,717 hectares in 2 separate claims located in New Brunswick. In addition, it holds interests in Stephenson Lake Gold project; Wilson Brook Gold project; York Gold project; Gold Brook property; and Pug Hole property. Slam Exploration Ltd. was incorporated in 1996 and is headquartered in Miramichi, Canada.
Full SLMXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.